Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Sickle Cell Anemia With Stem Cell Transplant
- Status
- TERMINATED
- Phase
- NA
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
- Status
- COMPLETED
- Phase
- PHASE2
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
- Status
- UNKNOWN
- Phase
- PHASE2
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Status
- TERMINATED
- Phase
- PHASE2
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Velcade Consolidation Bone Study
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
- Status
- COMPLETED
- Phase
- NA
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3